NKGen Biotech Files 8-K on Equity Sales
| Field | Detail |
|---|---|
| Company | Nkgen Biotech, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, definitive-agreement
Related Tickers: NKGN
TL;DR
NKGen Biotech filed an 8-K on 7/14/25 regarding unregistered equity sales.
AI Summary
On July 14, 2025, NKGen Biotech, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known as Graf Acquisition Corp. IV, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates potential new equity issuance or sales by NKGen Biotech, which could impact share dilution and the company's capital structure.
Risk Assessment
Risk Level: medium — Filings related to unregistered equity sales can signal financing needs or potential dilution, requiring closer examination.
Key Players & Entities
- NKGen Biotech, Inc. (company) — Registrant
- Graf Acquisition Corp. IV (company) — Former company name
- July 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific type of equity securities were sold unregistered?
The filing indicates unregistered sales of equity securities but does not specify the exact type in the provided text.
What is the purpose of these unregistered equity sales?
The filing does not explicitly state the purpose of the unregistered equity sales.
When was NKGen Biotech, Inc. formerly known as Graf Acquisition Corp. IV?
The date of the name change from Graf Acquisition Corp. IV to NKGen Biotech, Inc. was February 10, 2021.
What is NKGen Biotech's Standard Industrial Classification?
NKGen Biotech's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What is the business address of NKGen Biotech?
The business address of NKGen Biotech is 3001 Daimler St, Santa Ana, CA 92705.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding NKGen Biotech, Inc..